Skip to main content
Erschienen in: World Journal of Surgery 3/2014

01.03.2014

Establishment, Characterization and Comparison of Seven Authentic Anaplastic Thyroid Cancer Cell Lines Retaining Clinical Features of the Original Tumors

verfasst von: Naoyoshi Onoda, Masanori Nakamura, Naoki Aomatsu, Satoru Noda, Shinichiro Kashiwagi, Kosei Hirakawa

Erschienen in: World Journal of Surgery | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Anaplastic thyroid cancer (ATC) is thought to often be transformed from pre-existing differentiated thyroid cancer. It is one of the most aggressive malignancies and has a dismal prognosis due to its resistance to multimodal therapies. Basic exploratory studies using authentic ATC cell lines that retain its clinical features are necessary. We investigated the characteristics of seven ATC cell lines newly established at our institute to confirm their possible utility for basic studies.

Methods

Seven distinct cell lines from six patients were established. Their molecular characteristics and sensitivities to cytotoxic anti-cancer drugs were investigated and compared with each other, and with the clinical features of the original tumors.

Results

All cells showed extensive chromosomal abnormality and Pax8 expression, indicating human thyroid follicular cell origin. Vascular endothelial growth factor was secreted from all cells, suggesting possible candidacy for targeted therapy. Vimentin was expressed, but E-cadherin expression was lost in all cells but OCUT-1C, which showed different features from those of OCUT-1F derived from the same tumor, suggesting a mixture of cancer cell clones with various degrees of differentiation within a single ATC tumor. Cells were likely to show sensitivity for taxanes, indicating the usefulness of taxanes as the first-line chemotherapy. OCUT-2, a cell line with both B-Raf and PI3 KCA mutation, demonstrated the importance of molecular target-oriented therapy.

Conclusions

Basic studies using authentic ATC cell lines retaining the clinical features of the original tumor are useful models for investigating the mechanism of anaplastic transformation and exploring novel therapeutic strategies.
Literatur
1.
Zurück zum Zitat Smallridge RC (2012) Approach to the patient with anaplastic thyroid carcinoma. J Clin Endocrinol Metab 97:2566–2572PubMedCrossRef Smallridge RC (2012) Approach to the patient with anaplastic thyroid carcinoma. J Clin Endocrinol Metab 97:2566–2572PubMedCrossRef
2.
Zurück zum Zitat Akaishi J, Sugino K, Kitagawa W et al (2011) Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma. Thyroid 21:1183–1189PubMedCrossRef Akaishi J, Sugino K, Kitagawa W et al (2011) Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma. Thyroid 21:1183–1189PubMedCrossRef
3.
Zurück zum Zitat Sugitani I, Miyauchi A, Sugino K et al (2012) Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients. World J Surg 36:1247–1254. doi:10.1007/s00268-012-1437-z PubMedCrossRef Sugitani I, Miyauchi A, Sugino K et al (2012) Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients. World J Surg 36:1247–1254. doi:10.​1007/​s00268-012-1437-z PubMedCrossRef
4.
Zurück zum Zitat Cabanillas ME, Waguespack SG, Bronstein Y et al (2010) Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin Endocrinol Metab 95:2588–2595PubMedCrossRef Cabanillas ME, Waguespack SG, Bronstein Y et al (2010) Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin Endocrinol Metab 95:2588–2595PubMedCrossRef
5.
Zurück zum Zitat Benvenga S (2011) Emerging therapies in sight for the fight against dedifferentiated thyroid cancer. J Clin Endocrinol Metab 96:347–350PubMedCrossRef Benvenga S (2011) Emerging therapies in sight for the fight against dedifferentiated thyroid cancer. J Clin Endocrinol Metab 96:347–350PubMedCrossRef
6.
Zurück zum Zitat Rosove MH, Peddi PF, Glaspy JA (2013) BRAF V600E inhibition in anaplastic thyroid cancer. N Engl J Med 368:684–685PubMedCrossRef Rosove MH, Peddi PF, Glaspy JA (2013) BRAF V600E inhibition in anaplastic thyroid cancer. N Engl J Med 368:684–685PubMedCrossRef
7.
Zurück zum Zitat Kebebew E, Peng M, Reiff E et al (2006) A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer. Surgery 140:960–966 discussion 966–967 PubMedCrossRef Kebebew E, Peng M, Reiff E et al (2006) A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer. Surgery 140:960–966 discussion 966–967 PubMedCrossRef
8.
Zurück zum Zitat Reddi HV, Driscoll CB, Madde P et al (2013) Redifferentiation and induction of tumor suppressors miR-122 and miR-375 by the PAX8/PPARγ fusion protein inhibits anaplastic thyroid cancer: a novel therapeutic strategy. Cancer Gene Ther 20:267–275PubMedCrossRef Reddi HV, Driscoll CB, Madde P et al (2013) Redifferentiation and induction of tumor suppressors miR-122 and miR-375 by the PAX8/PPARγ fusion protein inhibits anaplastic thyroid cancer: a novel therapeutic strategy. Cancer Gene Ther 20:267–275PubMedCrossRef
9.
Zurück zum Zitat Schweppe RE, Klopper JP, Korch C et al (2008) Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 93:4331–4341PubMedCrossRef Schweppe RE, Klopper JP, Korch C et al (2008) Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 93:4331–4341PubMedCrossRef
10.
Zurück zum Zitat Ogisawa K, Onoda N, Ishikawa T et al (2002) Establishment and characterization of OCUT-1, an undifferentiated thyroid cancer cell line expressing high level of telomerase. J Surg Oncol 80:197–203PubMedCrossRef Ogisawa K, Onoda N, Ishikawa T et al (2002) Establishment and characterization of OCUT-1, an undifferentiated thyroid cancer cell line expressing high level of telomerase. J Surg Oncol 80:197–203PubMedCrossRef
11.
12.
Zurück zum Zitat Nobuhara Y, Onoda N, Yamashita Y et al (2005) Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines. Br J Cancer 92:1110–1116PubMedCentralPubMedCrossRef Nobuhara Y, Onoda N, Yamashita Y et al (2005) Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines. Br J Cancer 92:1110–1116PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat Chung SH, Onoda N, Ishikawa T et al (2002) Peroxisome proliferator-activated receptor gamma activation induces cell cycle arrest via the p53-independent pathway in human anaplastic thyroid cancer cells. Jpn J Cancer Res 93:1358–1365PubMedCrossRef Chung SH, Onoda N, Ishikawa T et al (2002) Peroxisome proliferator-activated receptor gamma activation induces cell cycle arrest via the p53-independent pathway in human anaplastic thyroid cancer cells. Jpn J Cancer Res 93:1358–1365PubMedCrossRef
14.
Zurück zum Zitat Tsutsui K (1995) Treatment for anaplastic carcinoma of the thyroid. Jpn J Cancer Clin 41:137–144 (in Japanese) Tsutsui K (1995) Treatment for anaplastic carcinoma of the thyroid. Jpn J Cancer Clin 41:137–144 (in Japanese)
15.
Zurück zum Zitat Onoda N, Aomatsu N, Nakamura M et al (2011) Basic study of anaplastic thyroid carcinoma using authentic cell lines. Endocr Surg 28:238–243 (in Japanese) Onoda N, Aomatsu N, Nakamura M et al (2011) Basic study of anaplastic thyroid carcinoma using authentic cell lines. Endocr Surg 28:238–243 (in Japanese)
16.
Zurück zum Zitat Liu D, Hou P, Liu Z et al (2009) Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin. Cancer Res 69:7311–7319PubMedCentralPubMedCrossRef Liu D, Hou P, Liu Z et al (2009) Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin. Cancer Res 69:7311–7319PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Liu J, Brown RE (2010) Immunohistochemical detection of epithelialmesenchymal transition associated with stemness phenotype in anaplastic thyroid carcinoma. Int J Clin Exp Pathol 3:755–762PubMedCentralPubMed Liu J, Brown RE (2010) Immunohistochemical detection of epithelialmesenchymal transition associated with stemness phenotype in anaplastic thyroid carcinoma. Int J Clin Exp Pathol 3:755–762PubMedCentralPubMed
18.
Zurück zum Zitat Knauf JA, Sartor MA, Medvedovic M et al (2011) Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling. Oncogene 30:3153–3162PubMedCentralPubMedCrossRef Knauf JA, Sartor MA, Medvedovic M et al (2011) Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling. Oncogene 30:3153–3162PubMedCentralPubMedCrossRef
19.
Zurück zum Zitat Nakamura T, Yana I, Kobayashi T et al (1992) p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas. Jpn J Cancer Res 83:1293–1298PubMedCrossRef Nakamura T, Yana I, Kobayashi T et al (1992) p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas. Jpn J Cancer Res 83:1293–1298PubMedCrossRef
20.
Zurück zum Zitat Salvatore G, Nappi TC, Salerno P et al (2007) A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. Cancer Res 67:10148–10158PubMedCrossRef Salvatore G, Nappi TC, Salerno P et al (2007) A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. Cancer Res 67:10148–10158PubMedCrossRef
21.
Zurück zum Zitat Kammori M, Onoda N, Nakamura K et al (2006) Specific subtelomere loss on chromosome der(11)t(3;11)(q23;q23)x2 in anaplastic thyroid cancer cell line OCUT-1. Int J Mol Med 18:9–16PubMed Kammori M, Onoda N, Nakamura K et al (2006) Specific subtelomere loss on chromosome der(11)t(3;11)(q23;q23)x2 in anaplastic thyroid cancer cell line OCUT-1. Int J Mol Med 18:9–16PubMed
22.
Zurück zum Zitat Nappi TC, Salerno P, Zitzelsberger H et al (2009) Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma. Cancer Res 69:1916–1923PubMedCrossRef Nappi TC, Salerno P, Zitzelsberger H et al (2009) Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma. Cancer Res 69:1916–1923PubMedCrossRef
23.
Zurück zum Zitat Matsuse M, Sasaki K, Nishihara E et al (2012) Copy number alteration and uniparental disomy analysis categorizes Japanese papillary thyroid carcinomas into distinct groups. PLoS One 7:e36063PubMedCentralPubMedCrossRef Matsuse M, Sasaki K, Nishihara E et al (2012) Copy number alteration and uniparental disomy analysis categorizes Japanese papillary thyroid carcinomas into distinct groups. PLoS One 7:e36063PubMedCentralPubMedCrossRef
24.
Zurück zum Zitat Finn S, Smyth P, O’Regan E et al (2007) Low-level genomic instability is a feature of papillary thyroid carcinoma: an array comparative genomic hybridization study of laser capture microdissected papillary thyroid carcinoma tumors and clonal cell lines. Arch Pathol Lab Med 131:65–73PubMed Finn S, Smyth P, O’Regan E et al (2007) Low-level genomic instability is a feature of papillary thyroid carcinoma: an array comparative genomic hybridization study of laser capture microdissected papillary thyroid carcinoma tumors and clonal cell lines. Arch Pathol Lab Med 131:65–73PubMed
25.
Zurück zum Zitat Ain KB, Egorin MJ, DeSimone PA (2000) Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 10:587–594PubMedCrossRef Ain KB, Egorin MJ, DeSimone PA (2000) Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 10:587–594PubMedCrossRef
26.
Zurück zum Zitat Higashiyama T, Ito Y, Hirokawa M et al (2010) Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma. Thyroid 20:7–14PubMedCrossRef Higashiyama T, Ito Y, Hirokawa M et al (2010) Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma. Thyroid 20:7–14PubMedCrossRef
27.
Zurück zum Zitat Kawada K, Kitagawa K, Kamei S et al (2010) The feasibility study of docetaxel in patients with anaplastic thyroid cancer. Jpn J Clin Oncol 40:596–599PubMedCrossRef Kawada K, Kitagawa K, Kamei S et al (2010) The feasibility study of docetaxel in patients with anaplastic thyroid cancer. Jpn J Clin Oncol 40:596–599PubMedCrossRef
28.
Zurück zum Zitat Smallridge RC, Ain KB, Asa SL et al (2012) American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 22:1104–1139PubMedCrossRef Smallridge RC, Ain KB, Asa SL et al (2012) American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 22:1104–1139PubMedCrossRef
29.
Zurück zum Zitat D’Agostino M, Voce P, Celano M et al (2012) Sunitinib exerts only limited effects on the proliferation and differentiation of anaplastic thyroid cancer cells. Thyroid 22:138–144PubMedCrossRef D’Agostino M, Voce P, Celano M et al (2012) Sunitinib exerts only limited effects on the proliferation and differentiation of anaplastic thyroid cancer cells. Thyroid 22:138–144PubMedCrossRef
30.
Zurück zum Zitat Hoffmann S, Wunderlich A, Celik I et al (2006) Paneling human thyroid cancer cell lines for candidate protein for targeting anti-angiogenic therapy. J Cell Biochem 98:954–965PubMedCrossRef Hoffmann S, Wunderlich A, Celik I et al (2006) Paneling human thyroid cancer cell lines for candidate protein for targeting anti-angiogenic therapy. J Cell Biochem 98:954–965PubMedCrossRef
31.
Zurück zum Zitat Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666–2676PubMedCrossRef Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666–2676PubMedCrossRef
32.
Zurück zum Zitat Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Eng J Med 350:2335–2342CrossRef Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Eng J Med 350:2335–2342CrossRef
Metadaten
Titel
Establishment, Characterization and Comparison of Seven Authentic Anaplastic Thyroid Cancer Cell Lines Retaining Clinical Features of the Original Tumors
verfasst von
Naoyoshi Onoda
Masanori Nakamura
Naoki Aomatsu
Satoru Noda
Shinichiro Kashiwagi
Kosei Hirakawa
Publikationsdatum
01.03.2014
Verlag
Springer US
Erschienen in
World Journal of Surgery / Ausgabe 3/2014
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-013-2409-7

Weitere Artikel der Ausgabe 3/2014

World Journal of Surgery 3/2014 Zur Ausgabe

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Deutlich weniger Infektionen: Wundprotektoren schützen!

08.05.2024 Postoperative Wundinfektion Nachrichten

Der Einsatz von Wundprotektoren bei offenen Eingriffen am unteren Gastrointestinaltrakt schützt vor Infektionen im Op.-Gebiet – und dient darüber hinaus der besseren Sicht. Das bestätigt mit großer Robustheit eine randomisierte Studie im Fachblatt JAMA Surgery.

Chirurginnen und Chirurgen sind stark suizidgefährdet

07.05.2024 Suizid Nachrichten

Der belastende Arbeitsalltag wirkt sich negativ auf die psychische Gesundheit der Angehörigen ärztlicher Berufsgruppen aus. Chirurginnen und Chirurgen bilden da keine Ausnahme, im Gegenteil.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.